liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Feasibility of home delivery of pemetrexed in patients with advanced non-squamous non-small cell lung cancer
Guys and St Thomas NHS Fdn Trust, England.
Karolinska University of Jukhuset, Sweden.
Maidstone and Tunbridge Wells NHS Trust, England.
Calderdale and Huddersfield NHS Trust, England.
Show others and affiliations
2015 (English)In: Lung Cancer, ISSN 0169-5002, E-ISSN 1872-8332, Vol. 89, no 2, 154-160 p.Article in journal (Refereed) Published
Abstract [en]

Objectives: To evaluate the feasibility and adherence to home delivery (HD) of pemetrexed maintenance treatment in patients with advanced non-squamous non-small cell lung cancer (nsqNSCLC). Materials and methods: Exploratory, prospective, single-arm, Phase II study in advanced nsqNSCLC patients, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0/1 that did not progress after 4 first-line induction cycles of a platinum doublet. The first cycle of pemetrexed (500 mg/m(2)) was hospital administered, further cycles were HD until progressive disease or discontinuation. Feasibility was assessed by the adherence rate to HD (probability of reversion to hospital administration or treatment discontinuation due to HD) as primary endpoint, and by health-related quality-of-life (HRQoL: EQ-5D, lung cancer symptom scale [LCSS]), satisfaction with HD, overall survival (OS), and safety. Results: 52 patients (UK and Sweden) received a median of 4 (range 1-19) pemetrexed maintenance cycles. Adherence rate up to Cycle 6 was 98.0% (95% confidence interval [CI]: 86.4%, 99.7%). All but 2 patients remained on HD. 1 patient discontinued after Cycle 1 (patient decision), and 1 after Cycle 6 (noncompliance with oral dexamethasone). 87% (33/38) of the patients preferred home to hospital treatment and in 90% (28/31) of cases, physicians were satisfied with distant management of patients. During HD Cycles 2-4 mean change from baseline ranged from 3.0 to 7.7 for EQ-5D visual analog scale. The 6-month OS rate was 73% (95% CI: 58%, 83%). 1 patient had an HD-related adverse event (device-related infection, Grade 2) and 1 patient died after Cycle 1, before HD, due to a possibly drug-related atypical pneumonia. Conclusion: HD of pemetrexed maintenance treatment in patients with advanced nsqNSCLC was feasible, safe, and preferred by patients, while maintaining HRQoL. Physicians were satisfied with distant patient management. (C) 2015 Elsevier Ireland Ltd. All rights reserved.

Place, publisher, year, edition, pages
Elsevier , 2015. Vol. 89, no 2, 154-160 p.
Keyword [en]
Pemetrexed; Maintenance; NSCLC; Home delivery; Quality of life; Adherence
National Category
Clinical Medicine
Identifiers
URN: urn:nbn:se:liu:diva-120645DOI: 10.1016/j.lungcan.2015.05.003ISI: 000358390000011PubMedID: 26101013OAI: oai:DiVA.org:liu-120645DiVA: diva2:847594
Available from: 2015-08-20 Created: 2015-08-20 Last updated: 2015-08-20

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Vikström, Anders
By organisation
Department of Clinical and Experimental MedicineFaculty of Health SciencesDepartment of Respiratory Medicine
In the same journal
Lung Cancer
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 34 hits
ReferencesLink to record
Permanent link

Direct link